CALGARY,
March 24, 2016 /PRNewswire/
- Oncolytics Biotech® Inc. ("Oncolytics" or
the "Company") (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY)
announced today that the Company has filed its management
information circular, which includes the nominees for election by
shareholders to Oncolytics' board of directors at its upcoming
Annual General Meeting (the "Meeting") to be held May 5, 2016 in Toronto,
Ontario, Canada.
In putting forward its slate of directors for the
coming year, the Company confirmed that Jim
Dinning has resigned from Oncolytics' board effective
March 10, 2016 to pursue other
interests. In addition, Robert
Schultz will not be standing for re-election in 2016 but
will serve as a board member until the Meeting.
"Since joining the Oncolytics board, both Mr.
Dinning and Mr. Schultz have made significant and highly valued
contributions to the Company," said Wayne
Pisano, Chairman of Oncolytics. "On behalf of the entire
board, I would like to thank both of them for their many years of
service to Oncolytics, and wish them well in their future
endeavors."
The Company's management information circular
will be available on SEDAR at www.sedar.com and on the Company's
website at www.oncolyticsbiotech.com. Oncolytics' Annual General
Meeting of shareholders will be held at the Toronto Board of Trade, 77 Adelaide St. West,
Suite 350, Toronto, Ontario, on
Thursday, May 5, 2016 at 4:00 p.m. ET.
About Oncolytics Biotech
Inc.
Oncolytics is a Calgary-based biotechnology company focused on
the development of oncolytic viruses as potential cancer
therapeutics. Oncolytics' clinical program includes a variety
of later-stage, randomized human trials in various indications
using REOLYSIN®, its proprietary formulation of the
human reovirus. For further information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains statements that
constitute "forward-looking information" within the meaning of
applicable securities legislation. Forward looking information is
typically identified by words such as "anticipate", "estimate",
"expect", "forecast", "may", "will", "could", "plan", "intend",
"should", "believe", "outlook", "project", "potential", "target"
and similar words suggesting future events or future performance.
This press release contains forward-looking information pertaining
to, among other things, the anticipated timing of the Company's
Annual Meeting of Shareholders. Various assumptions were
used in drawing the conclusions or making the forecasts contained
in the forward-looking information contained in this press release.
Forward-looking information is based on current expectations,
estimates and projections that involve a number of risks, which
could cause actual results to vary and in some instances to differ
materially from those anticipated by Oncolytics and described in
the forward-looking information contained in this press release.
Undue reliance should not be placed on forward-looking information.
Forward-looking information is based on the estimates and opinions
of Oncolytics' management at the time the information is
released. Except as may be required by law, Oncolytics
assumes no obligation to update publicly any such forward-looking
information and statements, whether as a result of new information,
future events, or otherwise.
SOURCE Oncolytics Biotech Inc.